PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) Alector, Inc.'s unaudited condensed consolidated financial statements for Q3 and YTD September 2024 are presented, showing a $117.0 million net loss for the nine-month period and $71.1 million from a January 2024 public offering Condensed Consolidated Balance Sheet Highlights (in thousands) | Metric | September 30, 2024 (in thousands) | December 31, 2023 (in thousands) | | :--- | :--- | :--- | | Cash, cash equivalents, and marketable securities | $457,202 | $548,861 | | Total Assets | $516,023 | $621,827 | | Total Liabilities | $397,090 | $487,669 | | Total Stockholders' Equity | $118,933 | $134,158 | Condensed Consolidated Statement of Operations Highlights (in thousands) | Metric | Three Months Ended Sep 30, 2024 (in thousands) | Three Months Ended Sep 30, 2023 (in thousands) | Nine Months Ended Sep 30, 2024 (in thousands) | Nine Months Ended Sep 30, 2023 (in thousands) | | :--- | :--- | :--- | :--- | :--- | | Collaboration Revenue | $15,342 | $9,109 | $46,318 | $81,872 | | Research and Development | $47,998 | $46,328 | $139,479 | $144,392 | | Net Loss | $(42,220) | $(44,475) | $(116,975) | $(88,957) | | Net Loss Per Share | $(0.43) | $(0.53) | $(1.22) | $(1.07) | Condensed Consolidated Statement of Cash Flows Highlights (in thousands) | Metric | Nine Months Ended Sep 30, 2024 (in thousands) | Nine Months Ended Sep 30, 2023 (in thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | $(174,877) | $(138,092) | | Net cash provided by investing activities | $65,729 | $83,847 | | Net cash provided by financing activities | $71,752 | $1,960 | - In January 2024, the company completed a public offering, issuing 10,869,566 shares of common stock which resulted in aggregate net proceeds of **$71.1 million**[21](index=21&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=17&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial condition and operations, highlighting progress in clinical programs for FTD and Alzheimer's, supported by collaboration revenues and a cash runway through 2026 - The company is focusing its development resources on key clinical candidates: **latozinemab** for frontotemporal dementia (FTD), and **AL002** and **AL101** for Alzheimer's disease (AD)[46](index=46&type=chunk) - Key clinical milestones achieved include target enrollment in the pivotal **Phase 3 INFRONT-3 trial for latozinemab**, **FDA Breakthrough Therapy Designation for latozinemab**, and the first participant dosed in the **PROGRESS-AD Phase 2 trial for AL101**[46](index=46&type=chunk) - As of September 30, 2024, the company had **$457.2 million** in cash, cash equivalents, and marketable securities, which is anticipated to provide a financial runway **through 2026**[48](index=48&type=chunk)[72](index=72&type=chunk) Comparison of Results of Operations (in thousands) | Metric | Three Months Ended Sep 30, 2024 (in thousands) | Three Months Ended Sep 30, 2023 (in thousands) | Nine Months Ended Sep 30, 2024 (in thousands) | Nine Months Ended Sep 30, 2023 (in thousands) | | :--- | :--- | :--- | :--- | :--- | | Collaboration Revenue | $15,342 | $9,109 | $46,318 | $81,872 | | R&D Expenses | $47,998 | $46,328 | $139,479 | $144,392 | | G&A Expenses | $15,778 | $13,364 | $44,587 | $41,767 | | Net Loss | $(42,220) | $(44,475) | $(116,975) | $(88,957) | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=26&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate sensitivity on its $457.2 million investment portfolio, with foreign currency risk deemed minimal due to U.S. dollar-denominated expenses - The company's primary market risk is **interest rate sensitivity**. An immediate **100 basis point change** in interest rates would cause a change in the fair value of its investment portfolio of approximately **$2.2 million** as of September 30, 2024[82](index=82&type=chunk) - Foreign currency risk is **not considered material** as expenses are generally denominated in **U.S. dollars**. A 10% change in exchange rates would **not have a material effect** on financial results[83](index=83&type=chunk) [Item 4. Controls and Procedures](index=27&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2024, with no material changes to internal control over financial reporting during the quarter - Based on an evaluation as of September 30, 2024, the Principal Executive Officer and Principal Financial and Accounting Officer concluded that the company's disclosure controls and procedures were **effective at a reasonable assurance level**[85](index=85&type=chunk) - **No changes in internal control over financial reporting** occurred during the quarter ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[86](index=86&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=28&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any legal proceedings expected to have a material adverse effect on its business - As of the filing date, the company is **not a party to any litigation or legal proceedings** that are expected to have a **material adverse effect** on its business[87](index=87&type=chunk) [Item 1A. Risk Factors](index=28&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks including limited operating history, substantial net losses, high uncertainty in neurodegenerative drug development, reliance on third parties, and the need for additional financing - The company has a **limited operating history**, **no approved products**, and has incurred **significant net losses** each year, with an **accumulated deficit of $827.1 million** as of September 30, 2024[91](index=91&type=chunk)[92](index=92&type=chunk)[93](index=93&type=chunk) - The business is **heavily dependent on the success of its product candidates**, which are in various stages of development. Drug development is **inherently risky**, particularly in the field of neurodegenerative diseases, which has seen **limited success**[96](index=96&type=chunk)[101](index=101&type=chunk)[106](index=106&type=chunk) - The company will need to obtain **substantial additional financing** to complete development and commercialization. Failure to raise capital could force **delays, reductions, or termination of its programs**[98](index=98&type=chunk) - The company **depends on collaborations with third parties** like GSK and AbbVie for development and commercialization, and these collaborations pose risks such as **potential termination or underperformance by partners**[162](index=162&type=chunk) - Clinical trials may face **substantial delays, enrollment difficulties, or fail to demonstrate safety and efficacy**. For example, **treatment-emergent MRI findings resembling ARIA** have been observed in the INVOKE-2 Phase 2 clinical trial[107](index=107&type=chunk)[111](index=111&type=chunk)[114](index=114&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=78&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period - **None**[233](index=233&type=chunk) [Item 5. Other Information](index=78&type=section&id=Item%205.%20Other%20Information) This section discloses the termination and adoption of new Rule 10b5-1 trading plans by the CFO for the potential sale of up to 84,357 shares of common stock - On September 12, 2024, CFO Marc Grasso **terminated a Rule 10b5-1 trading plan** adopted in August 2023[234](index=234&type=chunk) - On September 13, 2024, CFO Marc Grasso **adopted a new Rule 10b5-1 trading plan** for the exercise of options and sale of **up to 84,357 shares of common stock**, which will expire on September 13, 2025[234](index=234&type=chunk) [Item 6. Exhibits](index=78&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed with the Form 10-Q, including certifications from the Principal Executive Officer and Principal Financial Officer - The report includes **certifications from the Principal Executive Officer and Principal Financial Officer** pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002[235](index=235&type=chunk)[237](index=237&type=chunk)

[Executive Summary & Business Highlights](index=1&type=section&id=Executive%20Summary%20%26%20Business%20Highlights) Alector reported strong Q3 2024 financial results, a robust cash position, and key updates on its TREM2 and Progranulin clinical programs [Q3 2024 Overview](index=1&type=section&id=Q3%202024%20Overview) Alector reported strong Q3 2024 results, maintaining a **$457.2 million** cash position through 2026, and updated on key clinical programs AL002 and latozinemab - Alector's cash, cash equivalents, and investments totaled **$457.2 million** as of September 30, 2024, providing a financial runway through **2026**[1](index=1&type=chunk)[13](index=13&type=chunk) - Data from the INVOKE-2 Phase 2 trial, evaluating TREM2 agonist candidate AL002 in early Alzheimer's disease, is on track for release in **2024**[1](index=1&type=chunk)[2](index=2&type=chunk) - Participant baseline characteristics in the pivotal INFRONT-3 Phase 3 trial for latozinemab in FTD-GRN suggest a representative study population[1](index=1&type=chunk)[2](index=2&type=chunk) [CEO & R&D Head Commentary](index=1&type=section&id=CEO%20%26%20R%26D%20Head%20Commentary) CEO and R&D Head highlighted significant pipeline progress, including AL002's potential, INFRONT-3 patient data, PROGRESS-AD enrollment, and ABC technology advancements - AL002, the most advanced TREM2 candidate for early Alzheimer's disease, is expected to report INVOKE-2 Phase 2 trial data in **2024**, with potential for potent and durable therapeutic benefits[2](index=2&type=chunk) - The INFRONT-3 Phase 3 clinical trial for latozinemab in FTD-GRN has reported patient baseline characteristics suggesting a representative study population, with top-line data expected in **late 2025/early 2026**[2](index=2&type=chunk) - PROGRESS-AD, the Phase 2 trial of AL101/GSK4527226 in early Alzheimer's disease, has reached over **one-third** of its target enrollment[2](index=2&type=chunk) - Alector is actively advancing its proprietary Alector Brain Carrier (ABC) technology platform to improve the delivery of therapeutics to the brain for neurodegenerative diseases[2](index=2&type=chunk) [Recent Clinical Updates](index=2&type=section&id=Recent%20Clinical%20Updates) Alector provided comprehensive updates on its immuno-neurology pipeline, including TREM2 and Progranulin programs, and Alector Brain Carrier technology advancements [Immuno-Neurology Portfolio](index=2&type=section&id=Immuno-Neurology%20Portfolio) Alector updated its immuno-neurology pipeline, covering the TREM2 program (AL002) and Progranulin programs (latozinemab and AL101/GSK4527226) for neurodegenerative diseases [TREM2 Program (AL002)](index=2&type=section&id=TREM2%20Program%20(AL002)) The AL002 Phase 2 INVOKE-2 trial for early Alzheimer's disease is on track for 2024 results, with AbbVie holding a **$250 million** option for global rights - Results from the INVOKE-2 Phase 2 clinical trial of AL002 for early Alzheimer's disease are expected in **2024**[3](index=3&type=chunk) - **98%** of eligible participants who completed the planned treatment period of INVOKE-2 have elected to participate in the long-term extension (LTE) study[4](index=4&type=chunk) - A manuscript published in **October 2024** detailed preclinical and INVOKE-1 Phase 1 study results, showing AL002 engaged TREM2 and induced pharmacodynamic biomarker changes associated with microglial proliferation, survival, and phagocytic activity[5](index=5&type=chunk) - AbbVie has an exclusive option to globally develop and commercialize AL002, with a **$250 million** payment to Alector upon exercise[6](index=6&type=chunk) [Progranulin Programs (latozinemab (AL001) and AL101/GSK4527226)](index=2&type=section&id=Progranulin%20Programs%20(latozinemab%20(AL001)%20and%20AL101%2FGSK4527226)) The pivotal INFRONT-3 Phase 3 trial for latozinemab in FTD-GRN is on track for late 2025/early 2026 data, with AL101/GSK4527226's PROGRESS-AD trial progressing - The pivotal INFRONT-3 Phase 3 clinical trial of latozinemab for FTD-GRN is ongoing and on track, with enrollment completed in **October 2023** and a treatment duration of **96 weeks**[6](index=6&type=chunk) - Top-line data readout for INFRONT-3 is approaching in **late 2025/early 2026**[2](index=2&type=chunk) - Baseline characteristics of symptomatic INFRONT-3 participants were representative of the broader FTD-GRN registry population[7](index=7&type=chunk) - PROGRESS-AD, a Phase 2 clinical study evaluating AL101/GSK4527226 in early AD, has reached more than **one-third** of its target enrollment of **282 participants**[8](index=8&type=chunk) [Early Research Pipeline](index=3&type=section&id=Early%20Research%20Pipeline) Alector is advancing its proprietary Alector Brain Carrier (ABC) technology to optimize therapeutic delivery to the brain for next-generation immuno-neurology treatments - Alector continues to advance its Alector Brain Carrier (ABC), a proprietary, versatile blood-brain barrier technology platform[9](index=9&type=chunk) - The ABC technology platform enables customization of affinity, valency, and format to optimize effector function and half-life in preclinical models, aiming to improve delivery of therapeutics to the brain[9](index=9&type=chunk) [Third Quarter 2024 Financial Results](index=3&type=section&id=Third%20Quarter%202024%20Financial%20Results) Alector reported Q3 2024 financial results, detailing changes in collaboration revenue, operating expenses, net loss, and current cash position [Financial Performance Summary](index=3&type=section&id=Financial%20Performance%20Summary) Alector's Q3 2024 saw increased collaboration revenue, higher operating expenses, a reduced net loss, and a strong cash position despite a facility transition impairment [Collaboration Revenue](index=3&type=section&id=Collaboration%20Revenue) Collaboration revenue for Q3 2024 significantly increased year-over-year, driven by higher revenue recognition from the AL002 program | Metric | Q3 2024 (USD thousands) | Q3 2023 (USD thousands) | Change (YoY) | | :----- | :---------------------- | :---------------------- | :----------- | | Collaboration revenue | $15,342 | $9,109 | +$6,233 (+68.4%) | [Research and Development Expenses](index=3&type=section&id=Research%20and%20Development%20Expenses) Total R&D expenses for Q3 2024 modestly increased, driven by higher spending on AL101 programs and PROGRESS-AD Phase 2 clinical trial initiation | Metric | Q3 2024 (USD thousands) | Q3 2023 (USD thousands) | Change (YoY) | | :----- | :---------------------- | :---------------------- | :----------- | | Research and development | $47,998 | $46,328 | +$1,670 (+3.6%) | [General and Administrative Expenses](index=3&type=section&id=General%20and%20Administrative%20Expenses) G&A expenses increased in Q3 2024, primarily due to an impairment charge from a facility transition to the South San Francisco headquarters | Metric | Q3 2024 (USD thousands) | Q3 2023 (USD thousands) | Change (YoY) | | :----- | :---------------------- | :---------------------- | :----------- | | General and administrative | $15,778 | $13,364 | +$2,414 (+18.1%) | [Net Loss and EPS](index=3&type=section&id=Net%20Loss%20and%20EPS) Alector reported a reduced net loss and improved net loss per share for Q3 2024 compared to the prior year | Metric | Q3 2024 (USD million) | Q3 2023 (USD million) | Change (YoY) | | :----- | :-------------------- | :-------------------- | :----------- | | Net loss | $(42.2) | $(44.5) | -$2.3 (-5.2%) | | Net loss per share (USD) | $(0.43) | $(0.53) | -$0.10 (-18.9%) | [Cash Position](index=3&type=section&id=Cash%20Position) As of September 30, 2024, Alector maintained a strong cash position of **$457.2 million**, projected to fund operations through 2026 | Metric | As of Sep 30, 2024 (USD million) | As of Dec 31, 2023 (USD million) | Change (USD million) | | :----- | :------------------------------- | :------------------------------- | :------------------- | | Cash, cash equivalents, and investments | $457.2 | $548.9 | -$91.7 | [2024 Financial Guidance](index=4&type=section&id=2024%20Financial%20Guidance) Alector provided its full-year 2024 financial guidance, including projections for collaboration revenue and operating expenses [Full-Year 2024 Guidance](index=4&type=section&id=Full-Year%202024%20Guidance) Alector reiterated its full-year 2024 financial guidance, projecting collaboration revenue between **$60 million and $70 million** and total operating expenses between **$270 million and $290 million** | Metric | 2024 Guidance Range (USD million) | | :----- | :-------------------------------- | | Collaboration revenue | $60 - $70 | | Total R&D expenses | $210 - $220 | | Total G&A expenses | $60 - $70 | [Company Information](index=4&type=section&id=Company%20Information) This section provides an overview of Alector's immuno-neurology mission and includes standard forward-looking statements [About Alector](index=4&type=section&id=About%20Alector) Alector is a clinical-stage biotechnology company pioneering immuno-neurology, targeting immune dysfunction as a root cause of neurodegenerative diseases - Alector is a clinical-stage biotechnology company pioneering immuno-neurology for neurodegenerative diseases[15](index=15&type=chunk) - Its therapeutic approach targets immune dysfunction as a root cause of degenerative brain disorders[15](index=15&type=chunk) - Alector's product candidates are supported by biomarkers and seek to treat indications including Alzheimer's disease and genetically defined frontotemporal dementia patient populations[15](index=15&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section contains standard forward-looking statements regarding Alector's business, product candidates, and financial guidance, subject to risks in SEC filings - The press release contains forward-looking statements regarding business plans, product candidates, clinical trials, and financial guidance[16](index=16&type=chunk) - Such statements are subject to numerous risks and uncertainties, including those set forth in Alector's Quarterly Report on Form 10-Q filed with the SEC[16](index=16&type=chunk) - Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law[16](index=16&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) This section presents Alector's selected consolidated balance sheet and statement of operations data for the reported periods [Selected Consolidated Balance Sheet Data](index=5&type=section&id=Selected%20Consolidated%20Balance%20Sheet%20Data) Alector's consolidated balance sheet data shows a decrease across cash, total assets, liabilities, and stockholders' equity from December 31, 2023, to September 30, 2024 | Metric (USD thousands) | Sep 30, 2024 (USD thousands) | Dec 31, 2023 (USD thousands) | | :-------------------- | :--------------------------- | :--------------------------- | | Cash, cash equivalents, and marketable securities | $457,202 | $548,861 | | Total assets | $516,023 | $621,827 | | Total current liabilities (excluding deferred revenue) | $87,098 | $94,973 | | Deferred revenue (including current portion) | $248,202 | $293,820 | | Total liabilities | $397,090 | $487,669 | | Total stockholders' equity | $118,933 | $134,158 | [Consolidated Statement of Operations Data](index=5&type=section&id=Consolidated%20Statement%20of%20Operations%20Data) The consolidated statement of operations data for Q3 2024 shows increased collaboration revenue and reduced net loss, while the nine-month period reflects decreased revenue and increased net loss | Metric (USD thousands, except per share) | Q3 2024 (USD thousands) | Q3 2023 (USD thousands) | 9 Months Ended Sep 30, 2024 (USD thousands) | 9 Months Ended Sep 30, 2023 (USD thousands) | | :------------------------------------------ | :---------------------- | :---------------------- | :------------------------------------------ | :------------------------------------------ | | Collaboration revenue | $15,342 | $9,109 | $46,318 | $81,872 | | Research and development | $47,998 | $46,328 | $139,479 | $144,392 | | General and administrative | $15,778 | $13,364 | $44,587 | $41,767 | | Total operating expenses | $63,776 | $59,692 | $184,066 | $186,159 | | Loss from operations | $(48,434) | $(50,583) | $(137,748) | $(104,287) | | Other income, net | $6,214 | $7,360 | $20,853 | $18,876 | | Net loss before income tax | $(42,220) | $(43,223) | $(116,895) | $(85,411) | | Income tax expense | — | $1,252 | $80 | $3,546 | | Net loss | $(42,220) | $(44,475) | $(116,975) | $(88,957) | | Net loss per share, basic and diluted (USD) | $(0.43) | $(0.53) | $(1.22) | $(1.07) | | Shares used in computing net loss per share basic and diluted | 97,519,595 | 83,927,961 | 96,007,105 | 83,513,954 | [Contacts](index=6&type=section&id=Contacts) This section provides essential contact information for Alector's corporate, media, and investor relations [Alector Contacts](index=6&type=section&id=Alector%20Contacts) This section provides contact information for Alector's corporate communications, media relations, and investor relations - Contact information for Alector (Katie Hogan), media (Dan Budwick at 1AB), and investors (Laura Perry at Argot Partners) is provided[19](index=19&type=chunk)

Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer’s disease (AD), on track for 2024 Participant baseline characteristics in pivotal INFRONT-3 Phase 3 trial suggest a representative study population for testing the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN) $457.2 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. ...

Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.37%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.48 per share when it actually produced a loss of $0.38, delivering a surprise of 20.83%.Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38792 Alector, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-2933343 (State or other jurisdiction of in ...

Exhibit 99.1 Alector Reports Second Quarter 2024 Financial Results and Provides Business Update Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024 Patient baseline characteristics data for the INVOKE-2 trial confirm the intended study population for testing the effects of AL002, a novel TREM2 agonist, in early AD The latozinemab pivotal INFRONT-3 Phase 3 trial continues to progress well, supported by a recent U.S. Food and Drug Administ ...

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2024, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call. The event will be webcast live under the investor relations ...

--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD-- SOUTH SAN FRANCISCO, Calif., July 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno ...

Core Insights - Alector, Inc. is presenting its TREM2 and progranulin programs at the Alzheimer's Association International Conference® 2024, highlighting its focus on immuno-neurology for treating neurodegenerative diseases [1][2]. Group 1: Alector's Programs - The TREM2 Program (AL002) is being developed in collaboration with AbbVie, with poster presentations scheduled for July 28 and July 29, 2024, focusing on early Alzheimer's disease [1]. - The Progranulin Programs (latozinemab (AL001) and AL101/GSK4527226) are being developed in collaboration with GSK, with multiple poster presentations on July 28 and July 29, 2024, addressing various aspects of Alzheimer's disease [1]. Group 2: Conference Details - The Alzheimer's Association International Conference® 2024 will be held online and in Philadelphia from July 28 to August 1, 2024, with on-demand viewing of poster presentations starting on July 28 at 8:00 a.m. ET [1].

Group 1 - Alector, Inc. is a clinical-stage biotechnology company focused on immuno-neurology, which addresses immune dysfunction as a cause of neurodegenerative diseases [2] - The company will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference on June 27, 2024, with a webcast available for investors [1] - Alector's product candidates aim to treat conditions such as Alzheimer's disease and genetically defined frontotemporal dementia, supported by biomarkers [2] Group 2 - Alector is headquartered in South San Francisco, California, and is pioneering a novel therapeutic approach for neurodegenerative diseases [2] - The company has developed a broad portfolio of innate immune system programs to repair genetic mutations affecting the brain's immune system [2]